Healthcare

CRISPR & Cas Genes Market Value is Projected to Reach US$ 4.23 Bn By 2027

Precedence Research recently published a report on “CRISPR & Cas Genes Market (By Product and Services; By Application: Agricultural and Biomedical; End-User: Contract Research Organizations (CROs), Academics & Government Research Institutes and Biotechnology & Pharmaceutical Companies) – Global Market Size, Trends Analysis, Segment Forecasts, Regional Outlook 2020 – 2027”. Amid the COVID-19 crisis, The global CRISPR & Cas genes market size is projected to reach USD 4.23 billion by 2027, at a CAGR of 16.02% from 2020 – 2027.

The market revenue/volume with the help of widespread quantitative and qualitative insights, and forecasts of the market. This report presents breakdown of market into forthcoming and niche segments. Additionally, this research study gauges market revenue growth and its drift at global, regional, and country from 2016 to 2027. This research report evaluates CRISPR & Cas genes market on a global and regional level. It offers thorough analysis of market status, growth and forecast of the global CRISPR & Cas genes market for the period from 2016 to 2027. This research study offers historic data for years 2016 to 2027 along with a forecast from 2020 to 2027 based on value.

One of the most ground-breaking improvements in biology sector has its origins in the RNA-based defense system of bacteria, that encrypts CRISPR-associated shortened as Cas with clustered recurrently interspaced short palindromic repeats abbreviated as CRISPR proteins. It has been adapted to work as a programmable genome-engineering tool that has empowered stress-free manipulation and targeting of specific genomic sequences in fungi, plants, bacteria, and mammals, comprising humans. CRISPR possess capability to develop an alternate biotechnology treatment for appending or alternative for the prevailing single-antibody drugs.

CRISPR technology is a modest yet influential tool for genome editing. It permits researchers to effortlessly modify DNA sequences and alter gene function. Its various budding applications comprise averting and treating the spread of ailments, improving genetic defects, and refining crops.

Growth Factors

Progressions in the arena of genome editing have eased augmented adoption of CRISPR-Cas systems in diagnostics and in the valuation of evolutionary study in prokaryotes. This method is precisely utilized to comprehend the evolution of bacteria. Government organizations across the world have stimulated spending for genome editing developments thereby offering alluring growth prospects for global CRISPR and Cas genes market growth. The diversity of existing Cas proteins and elasticity of guide RNA production creates this practice a prevailing system for all genome editing applications. Also, the cumulative funding allotted for the genomics research and biotechnology development projects are further pushing the growth market throughout the forecast period.

Cumulative focus on development of innovative therapeutics on account of emergent pervasiveness of different genetic ailments and cancer is key influence projected to stimulate the progress of CRISPR and Cas genes marketplace during years to come. At present, gene editing landscape is also observing significant boost with several companies utilizing dissimilar versions of CRISPR-Cas along with corporations chasing alternative modalities with precise recompenses. This is because of the great amount of fundamental findings in basic gene editing. CRISPR-based discovery of nucleic acids is measured to be a profound, detailed, and trustworthy approach. Additionally, this technique needs testing to be done at a persistent temperature and eradicates the necessity of costly PCR platform..

Report Highlights

  • North America led the global market revenue with a stake of more than 36% in 2019. Factors accountable for this enormous growth include involvement of pharmaceutical enterprises in the expansion of novel therapeutics by installing genome editing protocols
  • At present, U.S. has the highest number of CRISPR publications across the globe, and endures to have the prevalent repository of cited papers.
  • A substantial amount of research studies conducted to progress disease-specific innovative therapies and existence of a enormous clinical pipeline that incorporates the application of gene-editing technology are anticipated to upsurge revenue generation for pharmaceutical and the biotechnology companies segment of the market

Scope of the Study

This CRISPR & Cas genes market report studies market dynamics, status and outlook especially in North America, Europe and Asia-Pacific, Latin America, Middle East and Africa. This research report offers scenario and forecast (revenue/volume), and categorizes market by players, type, application, and region. This report also studies global market prominence, competitive landscape, market share, growth rate market dynamics such as drivers, restraints and opportunities, and distributors and sales channel.

This research study also integrates Industry Chain analysis and Porter’s Five Forces Analysis. Further, this report offers competitive scenario which comprises collaborations, market concentration rate and expansions, mergers & acquisitions undertaken by companies.

Regional Snapshots

In 2019, North America conquered the whole CRISPR and Cas genes sector on account of reasons including occurrence of key companies, snowballing finance in genomics and biotechnology programs, and proven healthcare infrastructure among others. Augmented spending for research activities to offer reformed products for averting chronic diseases is predicted to push the progress of CRISPR and Cas genes market in North America. U.S. has the prevalent revenue contribution on account of reassuring healthcare policies, established healthcare sector and the high prevalence of chronic illnesses.

Asia Pacific is estimated to perceive the firmest development over the prediction period. China possesses a noteworthy footprint in the global CRISPR market arena and is progressively discovering genome-editing for the improvement of medicines. It has introduced numerous CRISPER-based clinical trials, particularly for treatment of cancer. Escalating requirement for genetically engineered treatment selections for chronic ailments including cancer is predicted to improve growth scenarios of the CRISPR market in Asia Pacific.

Key Players:

This report also provides detailed company profiles of the key market players. This research report also highlights the competitive landscape of the CRISPR & Cas genes market and ranks noticeable companies as per their occurrence in diverse regions across globe and crucial developments initiated by them in the market space. This research study also tracks and evaluates competitive developments, such as collaborations, partnerships, and agreements, mergers and acquisitions; novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.

Some of the prominent players in the CRISPR & Cas genes market include:

  • Caribou Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Cellectis
  • AstraZeneca
  • Editas Medicine, Inc.
  • Addgene
  • Egenesis
  • Horizon Discovery Group Plc
  • Intellia Therapeutics, Inc.
  • Genscrip
  • Danaher Corporation
  • Lonza
  • Merck KGaA
  • Synthego
  • Mammoth Biosciences
  • Inscripta, Inc.
  • Cibus
  • New England BioLabs
  • Takara Bio, Inc.

Segments Covered in the Report

By Product & Service

  • By Service
    • Microbial Gene Editing
    • Cell Line Engineering
    • gRNA Design
    • DNA Synthesis
  • By Product
    • Design Tool
    • Kits & Enzymes
    • Libraries
    • Antibodies
    • Others

By Application

  • Agricultural
  • Biomedical
    • Functional Genomics
    • Genome Engineering
    • Disease Model Studies
    • Epigenetics
    • Others
  • End-use Outlook
    • Contract Research Organizations (CROs),
    • Academics & Government Research Institutes
    • Biotechnology & Pharmaceutical Companies

By Regional Outlook

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Middle East & Africa
  • Latin America

Key Takeaways

  • Comprehensive analysis of the CRISPR & Cas genes market trends and shares from 2020 to 2027 at global and regional level to identify growth opportunities and analyze market developments
  • Exhaustive analysis of price trends with respect to resin type and region that are expected to impact the outlook of the global CRISPR & Cas genes market
  • Porters’ Five Forces analysis that highlights the bargaining power of buyers and suppliers to enable stakeholders to make profit-oriented business decisions
  • Extensive market outlook of key geographic regions along with market drivers, inhibitors, current & future market trends, and emerging applications
  • Comprehensive list of key potential clients across major end-use industries in different geographies
  • Thorough import-export analysis  across the globe
  • Regional level production output to comprehend the demand-supply scenario
  • Competitive landscape covers key companies’ profiling, market share analysis, market footprint analysis, competitive business strategies, channels, and competition matrix for key players

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers

Chapter 7. Global CRISPR & Cas Genes Market, By Product & Service

7.1. CRISPR & Cas Genes Market, by Product & Service Type, 2020-2027
7.1.1. Service
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Product
7.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 8. Global CRISPR & Cas Genes Market, By Application

8.1. CRISPR & Cas Genes Market, by Application, 2020-2027
8.1.1. Agricultural
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Biomedical
8.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 9. Global CRISPR & Cas Genes Market, By End-Use

9.1. CRISPR & Cas Genes Market, by End-Use, 2020-2027
9.1.1. Contract Research Organizations (CROs)
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Academics & Government Research Institutes
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Biotechnology & Pharmaceutical Companies
9.1.3.1. Market Revenue and Forecast (2016-2027)

Chapter 10. Global CRISPR & Cas Genes Market, Regional Estimates and Trend Forecast

10.1. North America
10.1.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.1.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.1.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.1.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.1.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.6.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.2.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.2.7.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.6.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.3.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.3.7.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.6.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.6.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.4.7.2. Market Revenue and Forecast, by Application (2016-2027)
10.4.7.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.5.4.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.4.3. Market Revenue and Forecast, by End-Use (2016-2027)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Product & Service (2016-2027)
10.5.5.2. Market Revenue and Forecast, by Application (2016-2027)
10.5.5.3. Market Revenue and Forecast, by End-Use (2016-2027)

Chapter 11. Company Profiles

11.1. Caribou Biosciences, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. F. Hoffmann-La Roche Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Cellectis
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. AstraZeneca
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Editas Medicine, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Addgene
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Egenesis
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Horizon Discovery Group Plc
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Intellia Therapeutics, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Genscrip
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Danaher Corporation
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. Lonza
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
11.13. Merck KGaA
11.13.1. Company Overview
11.13.2. Product Offerings
11.13.3. Financial Performance
11.13.4. Recent Initiatives
11.14. Synthego
11.14.1. Company Overview
11.14.2. Product Offerings
11.14.3. Financial Performance
11.14.4. Recent Initiatives
11.15. Mammoth Biosciences
11.15.1. Company Overview
11.15.2. Product Offerings
11.15.3. Financial Performance
11.15.4. Recent Initiatives
11.16. Inscripta, Inc.
11.16.1. Company Overview
11.16.2. Product Offerings
11.16.3. Financial Performance
11.16.4. Recent Initiatives
11.17. Cibus
11.17.1. Company Overview
11.17.2. Product Offerings
11.17.3. Financial Performance
11.17.4. Recent Initiatives
11.18. New England BioLabs
11.18.1. Company Overview
11.18.2. Product Offerings
11.18.3. Financial Performance
11.18.4. Recent Initiatives
11.19. Takara Bio, Inc.
11.19.1. Company Overview
11.19.2. Product Offerings
11.19.3. Financial Performance
11.19.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1108

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://precedenceresearchnews.wordpress.com

Follow us on LinkedIn | Twitter | Facebook

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Recent Posts

test

Read More

December 27, 2021

Drug of Abuse Testing Market Global Sales Are Expected To Reach $ 10.7 Bn by 2030

Precedence Research recently published a report on “Drug of Abuse Testing Market (By Drug Type: Alcohol, Cocaine, Marijuana/Cannabis, LSD, Opioids,… Read More

November 8, 2021

Digital Signage Market Rakes in US$ 38.63 Billion By 2030

Precedence Research recently published a report on “Digital Signage Market (By Component: Hardware, Software, Services; By Technology: LCD, LED, Projection;… Read More

November 8, 2021

Beverage Packaging Market to Grow At Rate of 6.4% Through 2030

Precedence Research recently published a report on “Beverage Packaging Market (By Material: Metal, Plastic, Glass, and Others; By Product: Bottles,… Read More

November 8, 2021

Paper Cups Market Rakes in $ 9.2 Billion By 2030

Precedence Research recently published a report on “Paper Cups Market (By type: Hot Paper Cups and Cold Paper Cups; By… Read More

November 8, 2021

Fire Protection System Market Rakes in $ 116.8 Bn By 2030

Precedence Research recently published a report on “Fire Protection System Market (By Product: Fire Detection, Fire Suppression, Fire Response, Fire… Read More

October 28, 2021

This website uses cookies.